OncoMatch/Clinical Trials/NCT06500884
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
Is NCT06500884 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies multiple treatments for multiple myeloma.
Treatment: Talquetamab · Prophylaxis A · Prophylaxis B · Prophylaxis C · Prophylaxis D · Ramantamig — The purpose of this study is to identify preventive treatments that can minimize the occurrence, severity, and duration of talquetamab-related taste changes (dysgeusia), during the prophylaxis (preventive) treatment phase, to better characterize the signs or symptoms of talquetamab-related taste changes and to better characterize the signs or symptoms of ramantamig-related taste changes.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Other
Cancer type
Multiple Myeloma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: proteasome inhibitor
triple-class exposed (received prior treatment with a PI, an IMiD, and anti CD38 mAb)
Must have received: IMiD
triple-class exposed (received prior treatment with a PI, an IMiD, and anti CD38 mAb)
Must have received: anti-CD38 monoclonal antibody
triple-class exposed (received prior treatment with a PI, an IMiD, and anti CD38 mAb)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California San Francisco · San Francisco, California
- Colorado Blood Cancer Institute · Denver, Colorado
- Yale University School Of Medicine · New Haven, Connecticut
- Icahn School of Medicine at Mt. Sinai · New York, New York
- University of Rochester Medical Center · Rochester, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06500884 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received proteasome inhibitor and IMiD.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages